The epidemiology and clinical outcome of hepatitis D virus (delta) infection in Jordan. 1987

A U Toukan, and O A Abu-el-Rub, and S A Abu-Laban, and M S Tarawneh, and M F Kamal, and S C Hadler, and K Krawczynski, and H S Margolis, and J E Maynard
Department of Medicine, Jordan University Hospital, Faculty of Medicine, Amman.

The epidemiology and clinical outcome of hepatitis D viral infection in HBsAg-positive acute hepatitis, chronic liver disease, primary hepatocellular carcinoma and the symptomless carrier state was studied in Jordan. The prevalence of hepatitis D viral infection was significantly higher in patients with chronic liver disease (18/79, 23%) and acute hepatitis (17/108, 16%) than in symptomless HBsAg carriers (2/136, 2%). The highest prevalence of hepatitis D viral infection was found in patients with primary hepatocellular carcinoma (10/15, 67%) who were also significantly older than such patients without hepatitis D viral infection. Antihepatitis D virus IgM was detected persistently in 83% of patients with antihepatitis D virus-positive chronic liver disease and transiently in 41% of patients with acute hepatitis. A trend to increased mortality was observed in acute hepatitis D viral superinfection (25%) compared to hepatitis D viral coinfection (0%) and to antihepatitis D virus-negative HBsAg-positive acute hepatitis (4%). In patients with established chronic liver disease, however, neither survival nor histological parameters of disease activity were significantly different in the antihepatitis D virus-positive and antihepatitis D virus-negative groups. While the early stage of hepatitis D viral superinfection is associated with increased mortality, it appears that in patients with late-stage chronic liver disease, severe histological activity subsides, and survival is no longer influenced by the factor of hepatitis D viral infection. However, primary hepatocellular carcinoma appears to complicate the course of those antihepatitis D virus-positive patients surviving beyond this stage.

UI MeSH Term Description Entries
D007597 Jordan A country in the MIDDLE EAST, northwest of Saudi Arabia, between Israel and Iraq. The capital is Amman.
D008107 Liver Diseases Pathological processes of the LIVER. Liver Dysfunction,Disease, Liver,Diseases, Liver,Dysfunction, Liver,Dysfunctions, Liver,Liver Disease,Liver Dysfunctions
D008113 Liver Neoplasms Tumors or cancer of the LIVER. Cancer of Liver,Hepatic Cancer,Liver Cancer,Cancer of the Liver,Cancer, Hepatocellular,Hepatic Neoplasms,Hepatocellular Cancer,Neoplasms, Hepatic,Neoplasms, Liver,Cancer, Hepatic,Cancer, Liver,Cancers, Hepatic,Cancers, Hepatocellular,Cancers, Liver,Hepatic Cancers,Hepatic Neoplasm,Hepatocellular Cancers,Liver Cancers,Liver Neoplasm,Neoplasm, Hepatic,Neoplasm, Liver
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D002353 Carrier State The condition of harboring an infective organism without manifesting symptoms of infection. The organism must be readily transmissible to another susceptible host. Asymptomatic Carrier State,Asymptomatic Infection Carrier,Inapparent Infection Carrier,Presymptomatic Carrier State,Presymptomatic Infection Carrier,Super-spreader Carrier,Superspreader Carrier,Asymptomatic Carrier States,Asymptomatic Infection Carriers,Carrier State, Asymptomatic,Carrier State, Presymptomatic,Carrier States,Carrier, Super-spreader,Carrier, Superspreader,Carriers, Super-spreader,Carriers, Superspreader,Inapparent Infection Carriers,Infection Carrier, Asymptomatic,Infection Carrier, Inapparent,Infection Carrier, Presymptomatic,Presymptomatic Carrier States,Presymptomatic Infection Carriers,Super spreader Carrier,Super-spreader Carriers,Superspreader Carriers
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003699 Hepatitis D INFLAMMATION of the LIVER in humans caused by HEPATITIS DELTA VIRUS, a defective RNA virus that can only infect HEPATITIS B patients. For its viral coating, hepatitis delta virus requires the HEPATITIS B SURFACE ANTIGENS produced by these patients. Hepatitis D can occur either concomitantly with (coinfection) or subsequent to (superinfection) hepatitis B infection. Similar to hepatitis B, it is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Amazon Black Fever,Black Fever, Amazon,Delta Hepatitis,Delta Infection,Delta Superinfection,Hepatitis, Delta,Labrea Disease,Infection, Delta,Superinfection, Delta,Delta Superinfections,Disease, Labrea,Diseases, Labrea,Fever, Amazon Black,Hepatitides, Delta,Infections, Delta,Labrea Diseases,Superinfections, Delta
D006509 Hepatitis B INFLAMMATION of the LIVER in humans caused by a member of the ORTHOHEPADNAVIRUS genus, HEPATITIS B VIRUS. It is primarily transmitted by parenteral exposure, such as transfusion of contaminated blood or blood products, but can also be transmitted via sexual or intimate personal contact. Hepatitis B Virus Infection
D006514 Hepatitis B Surface Antigens Those hepatitis B antigens found on the surface of the Dane particle and on the 20 nm spherical and tubular particles. Several subspecificities of the surface antigen are known. These were formerly called the Australia antigen. Australia Antigen,HBsAg,Hepatitis B Surface Antigen,Antigen, Australia
D006528 Carcinoma, Hepatocellular A primary malignant neoplasm of epithelial liver cells. It ranges from a well-differentiated tumor with EPITHELIAL CELLS indistinguishable from normal HEPATOCYTES to a poorly differentiated neoplasm. The cells may be uniform or markedly pleomorphic, or form GIANT CELLS. Several classification schemes have been suggested. Hepatocellular Carcinoma,Hepatoma,Liver Cancer, Adult,Liver Cell Carcinoma,Liver Cell Carcinoma, Adult,Adult Liver Cancer,Adult Liver Cancers,Cancer, Adult Liver,Cancers, Adult Liver,Carcinoma, Liver Cell,Carcinomas, Hepatocellular,Carcinomas, Liver Cell,Cell Carcinoma, Liver,Cell Carcinomas, Liver,Hepatocellular Carcinomas,Hepatomas,Liver Cancers, Adult,Liver Cell Carcinomas

Related Publications

A U Toukan, and O A Abu-el-Rub, and S A Abu-Laban, and M S Tarawneh, and M F Kamal, and S C Hadler, and K Krawczynski, and H S Margolis, and J E Maynard
January 1985, Hepatology (Baltimore, Md.),
A U Toukan, and O A Abu-el-Rub, and S A Abu-Laban, and M S Tarawneh, and M F Kamal, and S C Hadler, and K Krawczynski, and H S Margolis, and J E Maynard
January 1991, European journal of epidemiology,
A U Toukan, and O A Abu-el-Rub, and S A Abu-Laban, and M S Tarawneh, and M F Kamal, and S C Hadler, and K Krawczynski, and H S Margolis, and J E Maynard
December 1993, Liver,
A U Toukan, and O A Abu-el-Rub, and S A Abu-Laban, and M S Tarawneh, and M F Kamal, and S C Hadler, and K Krawczynski, and H S Margolis, and J E Maynard
September 2018, International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases,
A U Toukan, and O A Abu-el-Rub, and S A Abu-Laban, and M S Tarawneh, and M F Kamal, and S C Hadler, and K Krawczynski, and H S Margolis, and J E Maynard
August 2004, Nihon rinsho. Japanese journal of clinical medicine,
A U Toukan, and O A Abu-el-Rub, and S A Abu-Laban, and M S Tarawneh, and M F Kamal, and S C Hadler, and K Krawczynski, and H S Margolis, and J E Maynard
October 1995, Nihon rinsho. Japanese journal of clinical medicine,
A U Toukan, and O A Abu-el-Rub, and S A Abu-Laban, and M S Tarawneh, and M F Kamal, and S C Hadler, and K Krawczynski, and H S Margolis, and J E Maynard
October 2005, Journal of gastroenterology and hepatology,
A U Toukan, and O A Abu-el-Rub, and S A Abu-Laban, and M S Tarawneh, and M F Kamal, and S C Hadler, and K Krawczynski, and H S Margolis, and J E Maynard
June 1987, Tidsskrift for den Norske laegeforening : tidsskrift for praktisk medicin, ny raekke,
A U Toukan, and O A Abu-el-Rub, and S A Abu-Laban, and M S Tarawneh, and M F Kamal, and S C Hadler, and K Krawczynski, and H S Margolis, and J E Maynard
December 1985, European journal of epidemiology,
A U Toukan, and O A Abu-el-Rub, and S A Abu-Laban, and M S Tarawneh, and M F Kamal, and S C Hadler, and K Krawczynski, and H S Margolis, and J E Maynard
January 1987, Progress in clinical and biological research,
Copied contents to your clipboard!